Hemodilution and Outcome in Cardiac Surgery

Università Vita-Salute San Raffaele

Overview

An hematocrit of 21-25% is supposed to perform the best organ protection during cardiopulmonary bypass for cardiac surgery. The investigators want to establish the best timing for a transfusion (in patients with a predicted low hematocrit during cardiopulmonary bypass) and the efficacy of preprocedural hemodilution (in patients with a predicted high hematocrit during cardiopulmonary bypass) in patients undergoing cardiac surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Conditions

Kidney Failure Intraoperative Complications

Interventions

Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)PROCEDURE

Subgroup 1,with Ht\<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht\>25% bleed or not

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Undergoing cardiac surgery Exclusion Criteria: * Age \< 18 years old * Not signing written consent * Age \< 65 years old (subgroup 1) * Emergency, aortic stenosis, main left coronary stenosis (subgroup 2)

Locations (1)

Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia

Milan, Italy

Outcomes

Primary Outcomes

renal function

Secondary Outcomes

other organ damage

prolonged mechanical ventilation, Intensive Care Unit (ICU) and hospital stay

sepsis

exitus

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.